LANKLER DOUGLAS M 4
4 · PFIZER INC · Filed Feb 25, 2025
Insider Transaction Report
Form 4
PFIZER INCPFE
LANKLER DOUGLAS M
Executive Vice President
Transactions
- Exercise/Conversion
Common Stock
2025-02-22$30.17/sh+85,824$2,589,310→ 232,775 total - Exercise/Conversion
Stock Appreciation Rights
2025-02-22−85,824→ 0 totalExercise: $30.17From: 2025-02-22Exp: 2025-02-22→ Common Stock (85,824 underlying) - Tax Payment
Common Stock
2025-02-22$26.08/sh−76,565$1,996,815→ 152,876 total - Tax Payment
Common Stock
2025-02-22$26.30/sh−3,334$87,684→ 229,441 total
Holdings
- 1,951(indirect: By Rule 16b-3 Plan)
Common Stock
Footnotes (5)
- [F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- [F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- [F3]Price is the closing price of Pfizer common stock on February 21, 2025.
- [F4]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- [F5]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.